Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation
B Fattizzo, G Levati, R Cassin, W Barcellini - Drugs, 2019 - Springer
Eltrombopag is an orally available thrombopoietin receptor agonist indicated for the
treatment of immune thrombocytopenia (ITP). Beyond the effect on megakaryopoiesis, the …
treatment of immune thrombocytopenia (ITP). Beyond the effect on megakaryopoiesis, the …
Treatment of anemia in transfusion-dependent and non-transfusion-dependent lower-risk MDS: current and emerging strategies
Myelodysplastic syndromes (MDS) are a heterogeneous group of bone marrow disorders
with a highly diverse clinical course. For lower-risk MDS patients, therapeutic objectives aim …
with a highly diverse clinical course. For lower-risk MDS patients, therapeutic objectives aim …
Overexpression of WT1 and PRAME predicts poor outcomes of patients with myelodysplastic syndromes with thrombocytopenia
QS Huang, JZ Wang, YZ Qin, QZ Zeng, Q Jiang… - Blood …, 2019 - ashpublications.org
Thrombocytopenia is associated with life-threatening bleeding and is common in
myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be …
myelodysplastic syndromes (MDS). Robust molecular prognostic biomarkers need to be …
Myelodysplastic syndrome in hemodialysis patients
H Ayari, F Pasquier, K El Karoui, M Sallée… - Kidney International …, 2019 - kireports.org
(HD) patients, with the main cause being erythropoietin (EPO) deficiency. 1 To date,
erythropoiesisstimulating agents (ESAs) are the cornerstones of anemia therapy in HD …
erythropoiesisstimulating agents (ESAs) are the cornerstones of anemia therapy in HD …
[PDF][PDF] High-throughput hematology analysis with digital holographic microscopy
M Ugele - 2019 - opus4.kobv.de
For more than 100 years, the microscopic analysis of Giemsa-stained peripheral blood
smears has been the gold standard for the routine diagnosis of hematological disorders. To …
smears has been the gold standard for the routine diagnosis of hematological disorders. To …
Myelodysplastic syndromes–current diagnostics
B Celuch, I Urbanowicz, J Nowicka… - Journal of …, 2019 - diagnostykalaboratoryjna.eu
Myelodysplastic syndromes (MDS) are a heterogeneous group of hematopoietic neoplastic
diseases characterized by inefficient hematopoiesis, resistant peripheral cytopenias and an …
diseases characterized by inefficient hematopoiesis, resistant peripheral cytopenias and an …
Prise en charge des syndromes myélodysplasiques en 2019: mise au point
T Comont, K Delavigne, P Cougoul, S Bertoli… - La Revue de Médecine …, 2019 - Elsevier
Résumé Les syndromes myélodysplasiques forment un groupe hétérogène d'hémopathies
clonales caractérisé par des cytopénies périphériques et le risque de progression en …
clonales caractérisé par des cytopénies périphériques et le risque de progression en …
La signalisation du Brain-Derived Neurotrophic Factor et ses récepteurs dans les plaquettes
I Boukhatem - 2019 - papyrus.bib.umontreal.ca
Initialement découvert au cerveau, le Brain-derived neutrophic factor (BDNF) est un facteur
de croissance dont les mécanismes de relâche et la signalisation ont été bien étudiés dans …
de croissance dont les mécanismes de relâche et la signalisation ont été bien étudiés dans …
Zespoły mielodysplastyczne–współczesna diagnostyka
B Celuch, I Urbanowicz, J Nowicka… - Diagnostyka …, 2019 - diagnostykalaboratoryjna.eu
Zespoły mielodysplastyczne (MDS; myelodysplastic syndromes) są heterogenną grupą
chorób nowotworowych układu krwiotwórczego charakteryzującą się nieefektywną …
chorób nowotworowych układu krwiotwórczego charakteryzującą się nieefektywną …